

Special Issue

Measurements and Standards for Cancer Biomarkers in Clinical Testing

Message from the Guest Editor

Cancer biomarkers have been used to guide clinical decision-making, including risk assessment, screening, diagnosis, treatment selection, the determination of prognosis, the prediction of response to therapy, and monitoring response and outcomes.

The goal of this Special Issue is to present research articles, technical briefs, and scholarly and critical reviews on the topic reflected in the title, “Standards and Reference Materials for Cancer Biomarker Clinical Testing”. We are gathering contributions covering all aspects related to these efforts, including pre-analytical and analytical controls, standards, and reference material development for cancer biomarkers testing. Even though cancer is a disease of the genome, contributions may be related, but not limited, to DNA, RNA, proteins, metabolites, and current and prospective cancer biomarkers in tissue and liquid biopsy.

Guest Editor

Dr. Hua-Jun He

National Institute of Standards and Technology, Gaithersburg, MD, USA

Deadline for manuscript submissions

closed (31 December 2023)



Diagnostics

an Open Access Journal
by MDPI

Impact Factor 3.3
CiteScore 5.9
Indexed in PubMed



mdpi.com/si/141068

Diagnostics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
diagnostics@mdpi.com

[mdpi.com/journal/
diagnostics](https://mdpi.com/journal/diagnostics)





Diagnostics

an Open Access Journal
by MDPI

Impact Factor 3.3
CiteScore 5.9
Indexed in PubMed



[mdpi.com/journal/
diagnostics](https://mdpi.com/journal/diagnostics)



About the Journal

Message from the Editor-in-Chief

You are cordially invited to submit research articles, short communications, comprehensive reviews, case reports or interesting images for consideration and publication in *Diagnostics* (ISSN 2075-4418). *Diagnostics* is published in open access format – research articles, reviews and other contents are released on the Internet immediately after acceptance. The scientific community and the general public have unlimited and free access to the content as soon as it is published. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Andreas Kjaer
Department of Clinical Physiology, Nuclear Medicine & PET National
University Hospital, Rigshospitalet, University of Copenhagen,
Blegdamsvej 9, DK-2100 Copenhagen, Denmark

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, Inspec, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (Internal Medicine)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21 days after submission; acceptance to publication is undertaken in 2.6 days (median values for papers published in this journal in the first half of 2025).